Climate footprint of industry-sponsored in-human clinical trials: life cycle assessments of clinical trials spanning multiple phases and disease areas
TMC114FD1HTX1002 (ClinicalTrials.gov: NCT04208061), 77242113PSO2001 (ClinicalTrials.gov: NCT05364554), 42756493BLC2002 (ClinicalTrials.gov: NCT03473743), 54767414MMY3012 (ClinicalTrials.gov: NCT03277105), VAC18193RSV3006 (ClinicalTrials.gov: NCT05070546), R092670PSY3016 (ClinicalTrials.gov: NCT04072575) and 28431754DIA4032 (ClinicalTrials.gov: NCT04288778).
Authors
- Jason LaRoche (ORCID: https://orcid.org/0009-0002-3162-5735)
- Rodrigo A.F. Alvarenga (ORCID: https://orcid.org/0000-0002-6597-6421)
- Thomas Costelloe
- Wouter De Soete (ORCID: https://orcid.org/0000-0002-6236-549X)
- Jeremy Faludi (ORCID: https://orcid.org/0000-0002-9673-5305)
- Kristel Rens
- Jason Lanier
- Michael Collins
- Annemie Chiau
- Hugh Whetherly
Institutions
- Johnson & Johnson (United States) (US)
- Sustainability Institute (ZA)
- Environmental Resources Management (United Kingdom) (GB)
- Imperial Consultants (GB)
- Johnson & Johnson (Israel) (IL)
- Johnson & Johnson (Netherlands) (NL)
- Delft University of Technology (NL)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/bmjopen-2024-085364
- Citations
- 4
- Primary Topic
- Climate Change and Health Impacts
- Type
- article
- Field-Weighted Citation Impact
- 4.80
Funders
- Janssen Biotech